NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: GLENMARK · data 2026-11-01
Glenmark Pharmaceuticals Limited
In plain words
Price: 9.4% below its 52-week high of ₹2,537.6.
Delivery: 48.6% of traded shares were kept for delivery over the last 10 sessions, against 49.1% over the last 60.
Latest results: a net profit of ₹483 cr for the quarter ended Jun 2026 (+930.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹17,737 cr |
| Net profit (last 12 months) | ₹1,798 cr |
| Sales growth, 3 years (yearly) | 13.6% |
| Profit growth, 3 years (yearly) | 66.1% |
At a glance
Promoters 46.6% (unchanged in a year), pledged 0.0%, institutions 39.2%.
P/E 36.1, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 14.1%, ROCE 29.2%, operating margin 20.2%: how much profit it earns on the money it uses.
Debt/equity 0.06, Profit growth 66.1% and sales growth 13.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Healthy operating margin (20.2%).
- Profit grew 66.1% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
GLENMARK Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹4,018.48 crore, up 23.1% YoY and up 6.6% QoQ.
Net profit was ₹482.92 crore, up 930.3% YoY and a turn to profit from a loss last quarter.
Operating margin was 20% (17.8% a year ago).
EPS was ₹17.11, up 930.7% YoY and up 60.2% QoQ.
GLENMARK के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹4,018.48 करोड़; पिछले साल की तुलना में 23.1% की बढ़त, पिछली तिमाही की तुलना में 6.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹482.92 करोड़; पिछले साल की तुलना में 930.3% की बढ़त, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 20% (एक साल पहले 17.8%)।
EPS: ₹17.11; पिछले साल की तुलना में 930.7% की बढ़त, पिछली तिमाही की तुलना में 60.2% की बढ़त।
GLENMARKના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹4,018.48 કરોડ; ગયા વર્ષની સરખામણીએ 23.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 6.6% વધારો.
ચોખ્ખો નફો: ₹482.92 કરોડ; ગયા વર્ષની સરખામણીએ 930.3% વધારો, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 20% (એક વર્ષ પહેલાં 17.8%).
EPS: ₹17.11; ગયા વર્ષની સરખામણીએ 930.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 60.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 3/30: Delivery 52.1% over the last 20 sessions vs 50.0% in the 40 before (1.04x); shares delivered per day 1.06x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 26 schemes hold it, about ₹965 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 31 Aug 26Dividend Dividend ₹2.5 (ex-date) -1.8% next session
- 31 Jul 26Results Q1 FY27 results: profit +930.3% YoY +1.8% next session
- 29 May 26Results Q4 FY26 results: turned to loss vs a year ago -7.7% next session
- 30 Jan 26Results Q3 FY26 results: profit +15.9% YoY -2.3% next session
- 14 Nov 25Results Q2 FY26 results: profit +72.2% YoY -0.6% next session
- 3 Oct 25Dividend Dividend ₹2.5 (ex-date) +0.6% next session
- 15 Sept 25Dividend Dividend ₹2.5 (ex-date) -2.6% next session
- 14 Aug 25Results Q1 FY26 results: profit −86.2% YoY -2.7% next session
- 23 May 25Results Q4 FY25 results: turned to profit vs a year ago -2.9% next session
- 14 Feb 25Results Q3 FY25 results: turned to profit vs a year ago -2.7% next session
- 15 Nov 24Results Q2 FY25 results: turned to profit vs a year ago -3.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹4,018 cr | ₹483 cr | +930.3% | 20.0% | 17.11 |
| Mar 2026 | ₹3,771 cr | ₹-0 cr | -102.2% | 20.2% | 10.68 |
| Dec 2025 | ₹3,901 cr | ₹403 cr | +15.9% | 22.3% | 14.29 |
| Sept 2025 | ₹6,047 cr | ₹610 cr | +72.2% | 39.0% | 21.63 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% |
| Foreign institutions (FII) | 21.51% | 20.89% | 20.34% | 19.20% |
| Domestic institutions (DII) | 17.64% | 18.60% | 19.29% | 20.09% |
| Mutual funds | 15.61% | 16.76% | 16.80% | 17.86% |
| Retail investors | 7.99% | 7.91% | 7.63% | 7.85% |
| Number of shareholders | 2,08,414 | 2,11,418 | 1,96,105 | 2,01,584 |
Common questions
What was Glenmark Pharmaceuticals Limited's latest quarterly profit?
Glenmark Pharmaceuticals Limited reported a net profit of ₹483 cr for the quarter ended Jun 2026 (+930.3% on the same quarter a year earlier), on revenue of ₹4,018 cr.
How much do promoters hold in Glenmark Pharmaceuticals Limited?
Promoters held 46.65% of Glenmark Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Glenmark Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.06, which is very low.
What is Glenmark Pharmaceuticals Limited's P/E ratio?
About 36.1, based on the last 12 months' earnings and a price of ₹2,298.7 (data 2026-11-01).
What is the 52-week high and low of Glenmark Pharmaceuticals Limited?
The 52-week high is ₹2,537.6 and the 52-week low is ₹1,801.4.
Mutual funds holding Glenmark Pharmaceuticals Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 26 schemes holding about ₹965 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 4.78% | ₹167 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 3.56% | ₹62 cr |
| ADITYA BIRLA SUN LIFE QUANT FUND | Aditya Birla Sun Life Mutual Fund | 3.03% | ₹56 cr |
| Nippon India ETF Nifty Midcap 150 | Nippon India Mutual Fund | 0.87% | ₹33 cr |
| Nippon India Nifty Midcap 150 Index Fund | Nippon India Mutual Fund | 0.87% | ₹23 cr |
| Nippon India Nifty 500 Momentum 50 Index Fund | Nippon India Mutual Fund | 1.65% | ₹21 cr |
| Mirae Asset Nifty Midcap 150 ETF | Mirae Asset Mutual Fund | 0.87% | ₹16 cr |
| SBI Nifty Midcap 150 Index Fund | SBI Mutual Fund | 0.87% | ₹11 cr |
| ADITYA BIRLA SUN LIFE EQUITY SAVINGS FUND | Aditya Birla Sun Life Mutual Fund | 0.71% | ₹8 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.10% | ₹5 cr |
| ADITYA BIRLA SUN LIFE NIFTY MIDCAP 150 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.87% | ₹4 cr |
| SBI Nifty Midcap 150 Momentum 50 ETF | SBI Mutual Fund | 2.15% | ₹3 cr |
| Mirae Asset BSE Midcap 150 Momentum 30 ETF | Mirae Asset Mutual Fund | 2.28% | ₹2 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 3.10% | ₹2 cr |
| SBI Nifty200 Momentum 30 Index Fund | SBI Mutual Fund | 1.75% | ₹2 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
| Alkem Laboratories Ltd. | ₹5,113.5 | ₹61,277 cr | 28.4 | — | 17.8% | 17.8% | 0.15 | -7.7% |
| Biocon Limited | ₹351.8 | ₹57,310 cr | 104.6 | 1.6 | 1.4% | 3.5% | 0.45 | -7.4% |
| Abbott India Limited | ₹25,635 | ₹54,384 cr | 33.7 | — | 34.5% | 39.1% | 0.04 | -14.2% |
| Gland Pharma Ltd. | ₹3,095.9 | ₹51,112 cr | 45.2 | — | 10.5% | 12% | 0.03 | +62.6% |
| IPCA Laboratories Limited | ₹1,927.8 | ₹48,898 cr | 37.3 | — | 15.2% | 16.3% | 0.1 | +49.5% |
Compare GLENMARK with ALKEM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GLENMARK in NSE Scanner →